When might simple transfusion be used in SCD?

When might simple transfusion be used in SCD?

• A. During mild dehydration
• B. Only in HbSC patients
• C. During general anesthesia lasting more than 1 hour and for ACS
• D. Routine annual transfusions

Answer: (C)

Simple transfusion in sickle cell disease is used when there is an acute need to improve oxygen delivery and to dilute the amount of HbS in the circulation. In the perioperative setting, when general anesthesia is planned for longer than about an hour, transfusing normal donor red cells helps raise the overall oxygen-carrying capacity and reduces the risk of perioperative sickling during periods of potential hypoxia or poor perfusion. For acute chest syndrome, transfusion can similarly improve oxygenation by increasing red cell mass and lowering the relative HbS fraction, helping to reverse or prevent worsening hypoxemia. In more severe ACS, exchange transfusion may be favored for a faster and greater reduction in HbS, but simple transfusion remains a viable option in many cases. This approach isn’t used for mild dehydration, where fluid repletion is the priority. It isn’t limited to HbSC patients—transfusion decisions depend on the clinical scenario and HbS burden, not genotype alone. And it’s not routine annual transfusion therapy, which carries risks like alloimmunization and iron overload and is reserved for specific indications rather than ongoing, regular use.

Simple transfusion in sickle cell disease is used when there is an acute need to improve oxygen delivery and to dilute the amount of HbS in the circulation. In the perioperative setting, when general anesthesia is planned for longer than about an hour, transfusing normal donor red cells helps raise the overall oxygen-carrying capacity and reduces the risk of perioperative sickling during periods of potential hypoxia or poor perfusion. For acute chest syndrome, transfusion can similarly improve oxygenation by increasing red cell mass and lowering the relative HbS fraction, helping to reverse or prevent worsening hypoxemia. In more severe ACS, exchange transfusion may be favored for a faster and greater reduction in HbS, but simple transfusion remains a viable option in many cases.

This approach isn’t used for mild dehydration, where fluid repletion is the priority. It isn’t limited to HbSC patients—transfusion decisions depend on the clinical scenario and HbS burden, not genotype alone. And it’s not routine annual transfusion therapy, which carries risks like alloimmunization and iron overload and is reserved for specific indications rather than ongoing, regular use.